Concepedia

Author

Tadeusz Kubicki

Poznan University of Medical SciencesORCID

Also Known As

T Kubicki, T. Kubicki, Tadeusz F. Kubicki, Tadeusz Kubicki

53

Publications

482

Citations

9

H-Index

15

Concepts

All Affiliations

Poznan University of Medical SciencesWroclaw Medical UniversityMedical University of LublinUniversity of ChicagoInstytut Hematologii i Transfuzjologi
TK

About

Tadeusz Kubicki is an author at Poznan University of Medical Sciences specializing in oncology, hematology, and medicine.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

2

2

86

2

Health Sciences

1

1

17

3

Cell Biology

1

1

17

4

Immunology

1

1

69

5

Marrow Transplantation

1

1

69

Tadeusz Kubicki

×

8

Publications

311

Citations

8

H-Index

YearCitations

Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma

Jagoda Jasielec, Tadeusz Kubicki, Noopur Raje,

Blood

2020

72

Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial

Dominik Dytfeld, Tomasz Wróbel, Krzysztof Jamroziak,

The Lancet Oncology

2023

69

Comparative proteomic profiling of refractory/relapsed multiple myeloma reveals biomarkers involved in resistance to bortezomib-based therapy

Dominik Dytfeld, Magdalena Łuczak, Tomasz Wróbel,

Oncotarget

2016

68

Mass spectrometry–based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma

Tadeusz Kubicki, Dominik Dytfeld, David R. Barnidge,

Blood

2024

27

Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP)

Benjamin A. Derman, Ajay Major, Jennifer H. Cooperrider,

Blood Cancer Journal

2024

25

Comparative proteomic profiling of sera from patients with refractory multiple myeloma reveals potential biomarkers predicting response to bortezomib-based therapy

Magdalena Łuczak, Tadeusz Kubicki, Zuzanna Rzetelska,

Polskie Archiwum Medycyny Wewnętrznej

2017

18

Chromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group

Norbert Grząśko, Roman Hájek, Marek Hus,

Leukemia & lymphoma/Leukemia and lymphoma

2017

17

Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant

Benjamin A. Derman, Jennifer H. Cooperrider, Jacalyn Rosenblatt,

Blood Cancer Journal

2024

15

Page 1